Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
VRTX News
Vertex isn't your run-of-the-mill biotech stock. Warren Buffett famously said that he and his investing managers "attempt to be fearful when others are greedy,...
Vertex Pharmaceuticals recently announced progress across its kidney disease programs, including FDA Breakthrough Therapy Designation for povetacicept in IgA Ne...
Key Points Investors have feared that U.S. import tariffs may hurt companies’ earnings growth -- and weigh on stock performance. The following two players not...
Analyst ratings
60%
of 35 ratingsMore VRTX News
Trying to decide what to do with Vertex Pharmaceuticals stock right now? You are far from alone. After all, over the past year, the company’s share price dipped...
Vertex Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst on October 3. Analyst Evan Seigerman from BMO Capital maintained a...
Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INCORPORATED (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our Twi...
On CNBC's “Halftime Report Final Trades,” on Thursday, Jason Snipe, founder and chief investment officer of Odyssey Capital Advisors, said he likes ServiceNow,...
Citi raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $575 from $550 and keeps a Buy rating on the shares. The firm upped the price target aft...